Inhibiting autophagy: A novel approach for the treatment of renal cell carcinoma

Cancer Journal (United States)

Volumn 19, Issue 4, 2013, Pages 341-347

  Lotze, Michael T ^a   Maranchie, Jodi ^a   Appleman, Leonard ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

autophagy; Renal cell carcinoma

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; AUTOPHAGY INHIBITOR; BECLIN 1; CARMUSTINE; CHLOROQUINE; ERLOTINIB; EVEROLIMUS; FIBROBLAST GROWTH FACTOR; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYCHLOROQUINE; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RECOMBINANT INTERLEUKIN 2; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ACIDIFICATION; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CARCINOGENESIS; CELL DEATH; CELL MATURATION; CELL STRESS; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CLINICAL TRIAL (TOPIC); CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DNA DAMAGE; DRUG MEGADOSE; DRUG SAFETY; ENDOPLASMIC RETICULUM; ENZYME PHOSPHORYLATION; EXOCYTOSIS; GENOMIC INSTABILITY; GLIOBLASTOMA; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; KIDNEY CARCINOMA; LYSOSOME; LYSOSOME MEMBRANE; MELANOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN DEGRADATION; REVIEW; TOXOPLASMA GONDII; TUMOR IMMUNITY; VACCINATION;

EID: 84880950810     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31829da0d6     Document Type: Review

References (73)

1. Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30:406-410.
2. Ricketts C, Woodward ER, Killick P, et al. Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst. 2008;100: 1260-1262.
3. Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10:51-64.
4. Mathew R, Karp CM, Beaudoin B, et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell. 2009;137:1062-1075.
5. Jiang S, Dupont N, Castillo EF, et al. Secretory versus degradative autophagy: unconventional secretion of inflammatory mediators. J Innate Immun. 2013. [Epub ahead of print] PubMed PMID: 23445716.
6. Kroemer G, Levine B. Autophagic cell death: the story of a misnomer. Nat Rev Mol Cell Biol. 2008;9:1004-1010.
7. Jung CH, Jun CB, Ro SH, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell. 2009;20:1992-2003.
8. Ganley IG, Lam du H, Wang J, et al. ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy. J Biol Chem. 2009;284:12297- 12305.
9. Egan DF, Shackelford DB, Mihaylova MM, et al. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science. 2011;331:456-461.
10. Liang J, Shao SH, Xu ZX, et al. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat Cell Biol. 2007;9:218-224.
11. Singh K, Matsuyama S, Drazba JA, et al. Autophagy-dependent senescence in response to DNA damage and chronic apoptotic stress. Autophagy. 2012;8:236-251.
12. Ichimura Y, Kirisako T, Takao T, et al. A ubiquitin-like system mediates protein lipidation. Nature. 2000;408:488-492.
13. Shpilka T, Weidberg H, Pietrokovski S, et al. Atg8: an autophagyrelated ubiquitin-like protein family. Genome biology. 2011;12:226.
14. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin 1, a candidate tumor suppressor gene on chromosome 17q21. Genomics. 1999;59:59-65.
15. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 1999;402:672-676.
16. Qu X, Yu J, Bhagat G, et al. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J Clin Invest. 2003;112:1809-1820.
17. Yue Z, Jin S, Yang C, et al. Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA. 2003;100:15077-15082.
18. Takahashi Y, Hori T, Cooper TK, et al. Bif-1 haploinsufficiency promotes chromosomal instability and accelerates Myc-driven lymphomagenesis via suppression of mitophagy. Blood. 2013;121: 1622-1632.
19. Amaravadi RK, Lippincott-Schwartz J, Yin XM, et al. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011;17:654-666.
20. Karantza-Wadsworth V, Patel S, Kravchuk O, et al. Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev. 2007;21:1621-1635.
21. Young AR, Narita M, Ferreira M, et al. Autophagy mediates the mitotic senescence transition. Genes Dev. 2009;23:798-803.
22. Elgendy M, Sheridan C, Brumatti G, et al. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell. 2011;42:23-35.
23. Mathew R, Karantza-Wadsworth V, White E. Assessing metabolic stress and autophagy status in epithelial tumors. Methods Enzymol. 2009; 453:53-81.
24. Fujii S, Mitsunaga S, Yamazaki M, et al. Autophagy is activated in pancreatic cancer cells and correlates with poor patient outcome. Cancer Sci. 2008;99:1813-1819.
25. Bristol ML, Emery SM, Maycotte P, et al. Autophagy inhibition for chemosensitization and radiosensitization in cancer: do the preclinical data support this therapeutic strategy? J Pharmacol Exp Ther. 2013; 344:544-552.
26. Amaravadi RK, Yu D, Lum JJ, et al. Autophagy inhibition enhances therapy-induced apoptosis in a Myc-induced model of lymphoma. J Clin Invest. 2007;117:326-336.
27. Paglin S, Hollister T, Delohery T, et al. A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 2001;61:439-444.
28. Livesey KM, Tang D, Zeh HJ, et al. Autophagy inhibition in combination cancer treatment. Current Opin Investig Drugs. 2009;10: 1269-1279.
29. Levy GD, Munz SJ, Paschal J, et al. Incidence of hydroxychloroquine retinopathy in 1,207 patients in a large multicenter outpatient practice. Arthritis Rheum. 1997;40:1482-1486.
30. McAfee Q, Zhang Z, Samanta A, et al. Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency. Proc Natl Acad Sci USA. 2012;109: 8253-8258.
31. Hampe J, Franke A, Rosenstiel P, et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet. 2007;39:207-211.
32. Rioux JD, Xavier RJ, Taylor KD, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39:596-604.
33. Algazy KM, Schuchter LM, Demichele AM, et al. Combined mTOR inhibition and autophagy inhibition: phase I trial of temsirolimus and hydroxchloroquine in patients with advanced solid tumors. Proc Am Assoc Cancer Res. 2011:Abstract 4500.
34. Fecher LA, Schuchter LM, Evans T, et al. Combining chemotherapy with autophagy inhibition: phase I trial of dose-intense temozolomide and hydroxchloroquine in patients with advanced solid tumors. Proc Am Assoc Cancer Res. 2011:Poster 26-6.
35. Sotelo J, Briceno E, Lopez-Gonzalez MA. Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2006;144: 337-343.
36. Rosenfeld MR, Grossman SA, Brem S, et al. Pharmacokinetic analysis and pharmacodynamic evidence of autophagy inhibition in patients with newly diagnosed glioblastoma treated on a phase I trial of hydroxychloroquine in combination with adjuvant temozolomide and radiation (ABTC 0603). J Clin Oncol. 2010;28(suppl):Abstract 3086.
37. Goldberg SB, Supko JG, Neal JW, et al. A phase I study of erlotinib and hydroxychloroquine in advanced nonYsmall-cell lung cancer. J Thorac Oncol. 2012;7:1602-1608.
38. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of antiYPD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
39. Liu G, Bi Y, Wang R, et al. Self-eating and self-defense: autophagy controls innate immunity and adaptive immunity. J Leukoc Biol. 2013; 93:511-519.
40. Dengjel J, Schoor O, Fischer R, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA. 2005;102:7922-7927.
41. Nimmerjahn F, Milosevic S, Behrends U, et al. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol. 2003;33:1250-1259.
42. Li Y, Wang LX, Pang P, et al. Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res. 2011;17:7047-7057.
43. Li Y, Wang LX, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res. 2008;68:6889-6895.
44. Andrade RM, Wessendarp M, Gubbels MJ, et al. CD40 induces macrophage anti-Toxoplasma gondii activity by triggering autophagydependent fusion of pathogen-containing vacuoles and lysosomes. J Clin Invest. 2006;116:2366-2377.
45. Nakagawa I, Amano A, Mizushima N, et al. Autophagy defends cells against invading group A Streptococcus. Science. 2004;306: 1037-1040.
46. Ogawa M, Yoshimori T, Suzuki T, et al. Escape of intracellular Shigella from autophagy. Science. 2005;307:727-731.
47. Sanjuan MA, Dillon CP, Tait SW, et al. Toll-like receptor signalling in macrophages links the autophagy pathway to phagocytosis. Nature. 2007;450:1253-1257.
48. Nedjic J, Aichinger M, Emmerich J, et al. Autophagy in thymic epithelium shapes the T-cell repertoire and is essential for tolerance. Nature. 2008;455:396-400.
49. Casares N, Pequignot MO, Tesniere A, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691-1701.
50. Obeid M, Tesniere A, Ghiringhelli F, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13: 54-61.
51. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009;15:1170-1178.
52. Buchser WJ, Laskow TC, Pavlik PJ, et al. Cell-mediated autophagy promotes cancer cell survival. Cancer Res. 2012;72:2970-2979.
53. Wildenberg ME, Vos AC, Wolfkamp SC, et al. Autophagy attenuates the adaptive immune response by destabilizing the immunologic synapse. Gastroenterology. 2012;142:1493-1503 e6.
54. Noman MZ, Buart S, Van Pelt J, et al. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol. 2009;182:3510-3521.
55. Noman MZ, Janji B, Kaminska B, et al. Blocking hypoxia-induced autophagy in tumors restores cytotoxic T-cell activity and promotes regression. Cancer Res. 2011;71:5976-5986.
56. Liang X, De Vera ME, BuchserWJ, et al. Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res. 2012;72:2791-2801.
57. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356: 2271-2281.
58. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet. 2008;372:449-456.
59. Bray K, Mathew R, Lau A, et al. Autophagy suppresses RIP kinaseYdependent necrosis enabling survival to mTOR inhibition. PLoS One. 2012;7:e41831.
60. Xie X, White EP, Mehnert JM. Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS One. 2013;8:e55096.
61. Fan QW, Cheng C, Hackett C, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Science signaling. 2010; 3:ra81.
62. Xu CX, Zhao L, Yue P, et al. Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy. Cancer Biol Ther. 2011;12:549-555.
63. Chang Z, Shi G, Jin J, et al. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy. Int J Mol Med. 2013;31:1449-1456.
64. Ikeda T, Ishii KA, Saito Y, et al. Inhibition of autophagy enhances sunitinib-induced cytotoxicity in rat pheochromocytoma PC12 cells. J Pharmacol Sci. 2013;121:67-73.
65. Lin CI, Whang EE, Lorch JH, et al. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery. 2012;152:1142-1149.
66. Dandamudi UB, Ghebremichael MS, Sosman JA, et al. A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS). J Clin Oncol. 2010;28(suppl):abstr 4530.
67. King A, Selak MA, Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene. 2006;25:4675-4682.
68. Zhang H, Bosch-Marce M, Shimoda LA, et al. Mitochondrial autophagy is an HIF-1Ydependent adaptive metabolic response to hypoxia. J Biol Chem. 2008;283:10892-10903.
69. Mikhaylova O, Stratton Y, Hall D, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532-546.
70. Unlu S, Tang S, Wang E, et al. Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One. 2012;7:e38899.
71. Li G, Liang X, Lotze MT. HMGB1: the central cytokine for all lymphoid cells. Front Immunol. 2013;4:68.
72. Zhang Q, Kang R, Zeh HJ 3rd, et al. DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy. 2013;9: 451-458.
73. Guo ZS, Liu Z, Bartlett DL, et al. Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res. 2013;3:1-20.